Skip to main content
Top
Published in: Medical Oncology 3/2011

01-09-2011 | Original Paper

P53 gene polymorphisms and breast cancer risk in Arab women

Authors: Shafika Alawadi, Lina Ghabreau, Mervat Alsaleh, Zainab Abdulaziz, Mohamed Rafeek, Nizar Akil, Moussa Alkhalaf

Published in: Medical Oncology | Issue 3/2011

Login to get access

Abstract

The association between polymorphisms in the p53 tumor suppressor gene and breast cancer risk has been studied in many human populations with conflicting conclusions. However, similar studies in Arab women are not available, and the status of these polymorphisms in this ethnic population is not known. We investigated the status of four known p53 gene polymorphisms and their possible role in breast cancer risk in Arab women. Genotyping was performed for 288 breast cancer women and 188 controls to determine Pro47Ser, Arg72Pro, Intron 3 Ins16 bp and intron 6 (G > C) polymorphisms. The p53 variant Pro47Ser was detected only in one Kuwaiti breast cancer patient and was not detected in any of the control subjects. Frequency of Arg/Arg at codon 72 was 26.6% in controls and 28.1% in patients, Arg/Pro frequency was 59.6% in controls and 69.4% in patients, the Pro/Pro genotype was 13.8% in controls and 2.4% in patients. We observed that women with Pro/Pro genotype have decreased risk for developing breast cancer (OR = 0.166, 95% CI = 0.067–0.411, p < 0.001). The intron 3 genotypes were A1/A1 (48.9%), A1/A2 (40.6%) and A2/A2 (10.5%) in controls and A1/A1(42.4%), A1/A2 (52.8%) and A2/A2 (4.8%) in cases. The intron 6 genotypes were 92.4% (GG), 7.6% (GC) and 0% (CC) in controls and 96.5% (GG), 3.5% (GC) and 0% (CC) in cases. No statistically significant differences between patients and controls were observed for intron 3 and intron 6 polymorphisms. Our data show that proline homozygosity at p53 codon 72 is associated with decreased breast cancer risk in Arab women.
Literature
3.
go back to reference Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622–9.PubMedCrossRef Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622–9.PubMedCrossRef
4.
go back to reference Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMedCrossRef Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95–107.PubMedCrossRef
5.
go back to reference Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993;53:752–9.PubMed Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993;53:752–9.PubMed
6.
go back to reference Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–3.PubMed Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–3.PubMed
7.
go back to reference Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.PubMedCrossRef Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–65.PubMedCrossRef
8.
go back to reference Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25:3489–500.PubMedCrossRef Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25:3489–500.PubMedCrossRef
9.
go back to reference Sansone P, Storci G, Pandolfi S, Montanaro L, Chieco P, Bonafe M. The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer. 2007;96:1302–8.PubMedCrossRef Sansone P, Storci G, Pandolfi S, Montanaro L, Chieco P, Bonafe M. The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia. Br J Cancer. 2007;96:1302–8.PubMedCrossRef
10.
go back to reference Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–6.PubMedCrossRef Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, et al. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis. 1996;17:1313–6.PubMedCrossRef
11.
go back to reference Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11:1684–8.PubMed Langerød A, Bukholm IR, Bregård A, Lønning PE, Andersen TI, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11:1684–8.PubMed
12.
go back to reference Zhang Z, Wang M, Wu D, Wang M, Tong N, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2009 Jul 23. [Epub ahead of print]. Zhang Z, Wang M, Wu D, Wang M, Tong N, et al. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2009 Jul 23. [Epub ahead of print].
13.
go back to reference Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, et al. p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci. 2003;10:430–5.PubMedCrossRef Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, et al. p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci. 2003;10:430–5.PubMedCrossRef
14.
go back to reference Granja F, Morari J, Morari EC, Correa LA, Assumpção LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 2004;210:151–7.PubMedCrossRef Granja F, Morari J, Morari EC, Correa LA, Assumpção LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 2004;210:151–7.PubMedCrossRef
15.
go back to reference Hadhri-Guiga B, Toumi N, Khabir A, Sellami-Boudawara T, Ghorbel A, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet. 2007;178:89–93.PubMedCrossRef Hadhri-Guiga B, Toumi N, Khabir A, Sellami-Boudawara T, Ghorbel A, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet. 2007;178:89–93.PubMedCrossRef
16.
go back to reference Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer. 2003;103:431–3.PubMedCrossRef Suspitsin EN, Buslov KG, Grigoriev MY, Ishutkina JG, Ulibina JM, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer. 2003;103:431–3.PubMedCrossRef
17.
go back to reference De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, et al. The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev. 2008;32:140–3.PubMedCrossRef De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Bernard L, et al. The p53 Arg72Pro and Ins16 bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases. Cancer Detect Prev. 2008;32:140–3.PubMedCrossRef
18.
go back to reference Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, et al. The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001;3:346–9.PubMedCrossRef Marsh A, Spurdle AB, Turner BC, Fereday S, Thorne H, et al. The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia. Breast Cancer Res. 2001;3:346–9.PubMedCrossRef
19.
go back to reference Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B. Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep. 2009;22:1205–11.PubMed Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B. Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep. 2009;22:1205–11.PubMed
20.
go back to reference Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002;12:269–72.PubMedCrossRef Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics. 2002;12:269–72.PubMedCrossRef
21.
go back to reference Buyru N, Altinisik J, Demokan S, Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev. 2007;3:207–13.CrossRef Buyru N, Altinisik J, Demokan S, Dalay N. p53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev. 2007;3:207–13.CrossRef
22.
go back to reference Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, et al. Importance of TP53 codon 72, intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.PubMedCrossRef Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, et al. Importance of TP53 codon 72, intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer. 2008;8:32.PubMedCrossRef
23.
go back to reference Franeková M, Zúbor P, Stanclová A, Dussan CA, Bohusová T, et al. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma. 2007;54:155–61.PubMed Franeková M, Zúbor P, Stanclová A, Dussan CA, Bohusová T, et al. Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma. 2007;54:155–61.PubMed
24.
go back to reference Fiszer-Maliszewska Ł, Kazanowska B, Kuśnierczyk P, Mańczak M, Niepiekło W, et al. Is p53 intronic variant G13964C associated with predisposition to cancer? J Appl Genet. 2003;44:547–52.PubMed Fiszer-Maliszewska Ł, Kazanowska B, Kuśnierczyk P, Mańczak M, Niepiekło W, et al. Is p53 intronic variant G13964C associated with predisposition to cancer? J Appl Genet. 2003;44:547–52.PubMed
25.
go back to reference Xu Y, Yao L, Ouyang T, Li J, Wang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005;11:7328–33.PubMedCrossRef Xu Y, Yao L, Ouyang T, Li J, Wang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 2005;11:7328–33.PubMedCrossRef
26.
go back to reference Alkhalaf M, Al-Bustan S, Hamoda H, Abdella N. Polymorphism of p53 gene codon 72 in Kuwaiti with coronary artery disease and diabetes. Int J Cardiol. 2007;115:1–6.PubMedCrossRef Alkhalaf M, Al-Bustan S, Hamoda H, Abdella N. Polymorphism of p53 gene codon 72 in Kuwaiti with coronary artery disease and diabetes. Int J Cardiol. 2007;115:1–6.PubMedCrossRef
27.
go back to reference Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, et al. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Path Oncol Res. 2008. doi:10.1007/s12253-008-9129-6. Akkiprik M, Sonmez O, Gulluoglu BM, Caglar HB, Kaya H, et al. Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer. Path Oncol Res. 2008. doi:10.​1007/​s12253-008-9129-6.
28.
go back to reference Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266–70.PubMedCrossRef Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, et al. Is p53 polymorphism maintained by natural selection? Hum Hered. 1994;44:266–70.PubMedCrossRef
29.
go back to reference Singh V, Rastogi N, Mathur N, Singh K, Singh MP. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol. 2008;18:48–57.PubMedCrossRef Singh V, Rastogi N, Mathur N, Singh K, Singh MP. Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol. 2008;18:48–57.PubMedCrossRef
30.
go back to reference Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007;173:38–42.PubMedCrossRef Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007;173:38–42.PubMedCrossRef
31.
go back to reference Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 2008;8:96.PubMedCrossRef Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM, et al. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 2008;8:96.PubMedCrossRef
32.
go back to reference Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, et al. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol. 2008;29:145–51.PubMedCrossRef Vannini I, Zoli W, Tesei A, Rosetti M, Sansone P, et al. Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. Tumour Biol. 2008;29:145–51.PubMedCrossRef
Metadata
Title
P53 gene polymorphisms and breast cancer risk in Arab women
Authors
Shafika Alawadi
Lina Ghabreau
Mervat Alsaleh
Zainab Abdulaziz
Mohamed Rafeek
Nizar Akil
Moussa Alkhalaf
Publication date
01-09-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9505-4

Other articles of this Issue 3/2011

Medical Oncology 3/2011 Go to the issue